膀胱尿路上皮癌中巨噬细胞移动抑制因子表达的临床意义

摘要

目的检测巨噬细胞移动抑制因子在膀胱尿路上皮癌中的表达及临床意义。　　方法采用 Western bolt 方法检测40对膀胱癌与手术切缘非癌组织中巨噬细胞移动抑制因子蛋白表达并分析其变化规律；再应用免疫组织化学法检测75对术后固定的膀胱癌与切缘组织中巨噬细胞移动抑制因子的表达并分析其与膀胱尿路上皮癌生物学行为的关系。　　结果膀胱尿路上皮癌中巨噬细胞移动抑制因子的表达与TNM 分期呈正相关（P<0.05），并且在淋巴结转移阳性的膀胱尿路上皮癌中巨噬细胞移动抑制因子的表达显著高于淋巴结转移阴性患者，巨噬细胞移动抑制因子表达与膀胱尿路上皮癌患者生存期呈负相关（P=0.0341）。　　结论巨噬细胞移动抑制因子可能是膀胱尿路上皮癌变多阶段演进过程中的重要变化分子之一，可能成为膀胱尿路上皮癌分子诊断的生物标志。%Objective To detect the expression and the clinical significance of macrophage migration inhibitory factor (MIF) in urothelial carcinoma of the bladder. Methods Western bolt was used to detect MIF expression in 40 samples with bladder cancer and paired adjacent tissue samples and immunohistochemistry was used to examine the MIF expression in 75 formalin-fixed, paraffin-embedded samples with bladder cancer for retrospective analysis. Results MIF expression level increased significantly in bladder cancer patients with lymph node metastasis as compared with negative lymph node metastasis (P<0.05). Furthermore, MIF expression level correlated positively with TNM stages (P<0.05) and negatively with survival time of bladder cancer patients (P=0.0341). Conclusion MIF may be an important molecule in the evolution of urothelial carcinoma of the bladder and may become a biomarker for diagnosis of the bladder cancer.